期刊文献+

基于CYP2C9* 3和VKORC1-1639G>A基因多态性指导房颤患者华法林稳定剂量预测模型的验证与评价 被引量:1

Validation and evaluation of warfarin stable dose prediction model guided by CYP2C9* 3 and VKORC1-1639G>A gene polymorphisms in patients with atrial fibrillation
原文传递
导出
摘要 目的:验证评价4个基于CYP2C9*3和VKORC1-1639G>A基因多态性的华法林稳定剂量预测模型的准确性。方法:收集太和县人民医院2020年1月至2022年7月进行CYP2C9*3和VKORC1-1639G>A基因检测的非瓣膜性房颤患者,将CYP2C9*3和VKORC1基因型和患者基本信息代入华法林稳定剂量预测模型中得到预测剂量,以绝对误差均值和理想预测百分比作为准确性评价指标,应用SPSS 17.0软件进行统计分析。结果:88例房颤患者的CYP2C9*3、VKORC1-1639G>A基因频率均符合Hardy-Weinberg平衡。模型1、2、3、4华法林预测剂量分别为(2.82±0.78),(2.80±0.85),(2.47±0.30),(1.99±0.82)mg·d^(-1),实际剂量为(2.71±0.74)mg·d^(-1);4个模型的绝对误差均值分别为0.11、0.09、-0.24、-0.72 mg·d^(-1)。4个模型理想预测百分比分别为72.73%、70.45%、61.36%、20.45%,模型1最高,模型4最低。散点图结果显示:模型2和模型1预测剂量与实际剂量的相关性较好。一致性检验结果显示:预测剂量与实际剂量一致性最高的是模型1,最低的为模型4。结论:模型1和模型2可以较好地预测房颤患者华法林给药剂量。 OBJECTIVE To verify and evaluate the accuracy of four warfarin stable dose prediction models based on CYP2C9*3 and VKORC1-1639G>A gene polymorphisms.METHODS Non-valvular atrial fibrillation patients who underwent CYP2C9*3 and VKORC1-1639G>A gene detection in Taihe County People’s Hospital from January 2020 to July 2022 were collected. The CYP2C9*3 and VKORC1 genotypes and the basic information of the patients were substituted into the warfarin stable dose prediction model to obtain the predicted dose. The mean absolute error and the ideal prediction percentage were used as the accuracy evaluation indicators, and SPSS 17.0 software was used for statistical analysis.RESULTS The gene frequencies of CYP2C9*3 and VKORC1-1639G>A in 88 patients with atrial fibrillation were both in line with Hardy-Weinberg equilibrium. The predicted doses of warfarin in model 1, 2, 3 and 4 were(2.82±0.78),(2.80±0.85),(2.47±0.30) and(1.99±0.82)mg·d^(-1), respectively, and the actual dose was(2.71±0.74)mg·d^(-1). The mean absolute errors of the four models were 0.11, 0.09,-0.24, and-0.72 mg·d^(-1), respectively. The ideal prediction percentages of the four models were 72.73%, 70.45%, 61.36%, and 20.45%, respectively, and that of model 1 was the highest, and that of model 4 was the lowest. The scatter plot results showed that model 2 and model 1 had good correlation between the predicted dose and the actual dose. The results of consistency test showed that the consistency of model 1 was the highest;the consistency of model 4 was the lowest.CONCLUSION Model 1 and model 2 can better predict the dose of warfarin in patients with atrial fibrillation.
作者 李宇 冯晓俊 张蕾 史天陆 LI Yu;FENG Xiao-jun;ZHANG Lei;SHI Tian-lu(Taihe County People's Hospital of Anhui Province/Taihe Hospital Affiliated to Wannan Medical College,Anhui Fuyang 236600,China;First Affiliated Hospital of University of Science and Technology of China/Anhui Provincial Hospital,Anhui Hefei 230001,China)
出处 《中国医院药学杂志》 CAS 北大核心 2023年第3期285-289,共5页 Chinese Journal of Hospital Pharmacy
基金 皖南医学院校级科研项目(编号:JXYY202141)。
关键词 CYP2C9 VKORC1 基因多态性 华法林 预测模型 准确性 CYP2C9 VKORC1 gene polymorphism warfarin prediction model accuracy
作者简介 李宇,男,硕士,主管药师,研究方向:临床药学;通信作者:史天陆,男,博士,主任药师,研究方向:医院药学。
  • 相关文献

参考文献6

二级参考文献44

  • 1涂向东,江清华,兰风华.三种简易提取全血基因组DNA方法的比较[J].中国实验诊断学,2006,10(3):264-266. 被引量:29
  • 2U.S. Food and Drug Adiministration. FDA Approves Updated Warfarin (Coumadin) Prescribing Information [ EB/OL~. http :// www. fda. gov/bbs/topics/news/2007/newO1684, html.
  • 3Tan GM, Wu E, Lam YY, et al. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics, 2010, 11 : 439-448.
  • 4Shin J, Cao D, et al. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics, 2011,12 : 125-134.
  • 5Roper N, Storer B, Bona R, et al. Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. J Mol Diagn, 2010, 12: 283-291.
  • 6Wen MS, MTM Lee, Chen JJ, et al. Prospective Study of Warfarin Dosage Requirements Based on CYP2C9 and VKORC1 Genotypes. Clin pharmacol Ther, 2008, 84 : 83-89.
  • 7Yuan HY, Chen JJ, MTM Lee, et al. A novel functional VKORC1 promoter polymorphism is associated with inter- individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet, 2005, 14: 1745-1751.
  • 8Ohno M, Yamamoto A, Ono A, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol,2009, 65 : 1097-1103.
  • 9Pharmacogenomics knowledge base. www. pharmgkb, org.
  • 10Klein TE, Ahman RB, Eriksson Net al. Estimation of the warfarin dose with clinical and phannacogenetic data. N Engl J Med, 2009, 360: 753-764.

共引文献42

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部